ISO 21560:2020
ISO 21560:2020 General requirements of tissue-engineered medical products
CDN $130.00
Description
This document specifies general requirements for tissue-engineered medical products (TEMPs), which are used in regenerative medicine. With regard to safety, this document outlines requirements for materials, manufacture, quality control, and unintentional biological effects elicited by TEMPs. This document does not address requirements for clinical trials and efficacy.
This document is not applicable to tissue-engineered products used for diagnosis, ex-vivo testing or extracorporeal treatments of patients (e.g. dialysis with TEMP components). TEMPs containing viable xenogenic cells, genetically modified cells, or cells derived from abnormal cells or tissues (e.g. cancerous tissues) are also excluded from the scope. The combination of TEMPs with medical devices, with the exception of scaffolds comprised of synthetic and/or naturally-derived (e.g. animal sourced) materials, is also excluded from the scope.
NOTE International, national or regional regulations or requirements, or the Pharmacopeia also apply to specific topics covered in this document.
Edition
1
Published Date
2020-08-31
Status
PUBLISHED
Pages
11
Language
English
Format
Secure PDF
Secure – PDF details
- Save your file locally or view it via a web viewer
- Viewing permissions are restricted exclusively to the purchaser
- Device limits - 3
- Printing – Enabled only to print (1) copy
See more about our Environmental Commitment
Abstract
This document specifies general requirements for tissue-engineered medical products (TEMPs), which are used in regenerative medicine. With regard to safety, this document outlines requirements for materials, manufacture, quality control, and unintentional biological effects elicited by TEMPs. This document does not address requirements for clinical trials and efficacy.
This document is not applicable to tissue-engineered products used for diagnosis, ex-vivo testing or extracorporeal treatments of patients (e.g. dialysis with TEMP components). TEMPs containing viable xenogenic cells, genetically modified cells, or cells derived from abnormal cells or tissues (e.g. cancerous tissues) are also excluded from the scope. The combination of TEMPs with medical devices, with the exception of scaffolds comprised of synthetic and/or naturally-derived (e.g. animal sourced) materials, is also excluded from the scope.
NOTE International, national or regional regulations or requirements, or the Pharmacopeia also apply to specific topics covered in this document.
Previous Editions
Can’t find what you are looking for?
Please contact us at:
Related Documents
-
ISO 18965:2025 Medical devices – Examples of the application of the risk management process to cardiac valve replacement and repair systems
CDN $261.00 Add to cart -
ISO 8548:2025 Prosthetics and orthotics – Limb deficiencies – Part 3: Method of describing the residual limb after upper limb amputation
CDN $193.00 Add to cart -
ISO 27185:2012 Cardiac rhythm management devices – Symbols to be used with cardiac rhythm management device labels, and information to be supplied – General requirements
CDN $307.00 Add to cart -
ISO 8549:2020 Prosthetics and orthotics – Vocabulary – Part 4: Terms relating to limb amputation
CDN $85.00 Add to cart
